Arkolith/Insider Trading/RETA/Form 4

Meyer Colin John

Chief Innovation OfficerREATA PHARMACEUTICALS INC (RETA) · full profile →Form 4 · filed Sep 26, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
12
1 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 26, 2023Disposed to issuer(D)82K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 26, 2023Disposed to issuer(D)25K——0
Sep 26, 2023Disposed to issuer(D)70K——0
Sep 26, 2023Disposed to issuer(D)74K——0
Sep 26, 2023Disposed to issuer(D)24K——0
Sep 26, 2023Disposed to issuer(D)30K——0
Sep 26, 2023Disposed to issuer(D)18K——0
Sep 26, 2023Disposed to issuer(D)95K——0
Sep 26, 2023Disposed to issuer(D)90K——0
Sep 26, 2023Disposed to issuer(D)88K——0
Sep 26, 2023Disposed to issuer(D)36K——0
Sep 26, 2023Disposed to issuer(D)18K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-019538) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML